N/A N=15 Treatment

Intravenous Interferon During Liver Transplant

Hepatitis C · Cirrhosis

Bottom Line

View on ClinicalTrials.gov: NCT01192698 ↗

Enrolled (actual)

Serious AEs

20.0%

Results posted

Aug 2017

Primary outcome: Primary: HCV RNA Result — 924,082; 3,731,749 IU/ml

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: IV interferon (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Wake Forest University Health Sciences
Primary completion: Feb 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY HCV RNA Result	924,082; 3,731,749	—

Summary

The main goal of this study is to prevent liver allograft infection with Hepatitis C virus in hepatitis C positive patients undergoing liver transplantation. The hypothesis is that patients who receive ribavirin immediately before transplant and intravenous interferon alfa 2b during the anhepatic phase(while the liver is removed)will have sustained virologic response post liver transplant.

Eligibility Criteria

Inclusion Criteria

liver transplant for hepatitis c

Exclusion Criteria

allergy to interferon

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01192698). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.